Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study
Cyrille Hulin, Fritz Offner, Philippe Moreau, Murielle Roussel, Karim Belhadj, Lotfi Benboubker, Denis Caillot, Thierry Façon, Laurent Garderet, Frédérique Kuhnowski, Anne‐Marie Stoppa, Brigitte Kolb, Mourad Tiab, Kon‐Siong G. Jie, Matthijs Westerman, Jérôme Lambert, Lixia Pei, Véronique Vanquickelberghe, Carla de Boer, Jessica Vermeulen, Tobias Kampfenkel, Pieter Sonneveld, Niels W.C.J. van de Donk
Abstract
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib
Topics & Concepts
DaratumumabBortezomibMultiple myelomaMedicineDexamethasoneInternal medicineThalidomideTransplantationAutologous stem-cell transplantationOncologyMultiple Myeloma Research and TreatmentsChronic Myeloid Leukemia TreatmentsProtein Degradation and Inhibitors